D3 Bio

D3 Bio is a global biotechnology company dedicated to developing innovative and efficacious medicines for patients with serious or life-threatening illnesses, particularly focusing on oncology and immunology. Their unique approach prioritizes understanding unmet patient needs and leveraging those insights to guide the development of novel therapies. They boast a pipeline of pre-clinical stage oncology programs with first-in-class or best-in-class potential, aiming to create breakthrough precision medicines that match therapies to individual patients' disease biomarkers.

D3 Bio is backed by a syndicate of renowned investors including Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund. Their team boasts experience in multinational big pharma companies and possesses a strong understanding of the scientific and market requirements for translational drug development. They are committed to transforming the lives of patients worldwide by creating life-changing therapies that address the most difficult-to-treat, life-threatening or debilitating conditions.

D3 Bio is a global biotechnology company dedicated to developing innovative medicines that address the unmet needs of patients with serious or life-threatening conditions. They are committed to transforming the lives of patients worldwide by creating breakthrough precision medicines that target the disease biomarkers of individual patients, particularly in the fields of oncology and immunology.

D3 Bio promotes a culture of innovation and collaboration, driven by a shared commitment to developing breakthrough cancer therapies. They prioritize clinical insight and biomarker-driven research, fostering a team of experienced professionals with a track record of success in drug discovery and development. The company's global focus and partnerships with renowned investors underscore their commitment to tackling unmet patient needs worldwide. This translates to a dynamic and driven workplace where scientific excellence meets a strong patient-centric focus.